Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC health data API infrastructure connecting 500+ wearables and at-home lab tests for 140+ healthcare orgs; $18M Creandum Series A Mar 2025 supporting 2M+ connected devices and 500K+ tests annually competing with Validic and Terra API.
Junction is a United States-based health data infrastructure company — backed by Y Combinator with $18 million in Series A funding in March 2025 led by Creandum with participation from Point Nine, Amino Collective, and Inflect Health — providing digital health companies, research organizations, and healthcare technology platforms with a unified API infrastructure for collecting wearable device data (500+ supported devices including Apple Watch, Fitbit, Oura, Garmin, and continuous glucose monitors) and delivering at-home diagnostic test kits to patients with automated diagnostic data workflows that connect labs, wearables, and health systems. Founded and serving 140+ healthcare organizations including Found, Parsley Health, and Evidation, Junction supports 500,000+ lab tests annually and 2 million+ connected devices.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.